Free Trial
OTCMKTS:DDDX

3Dx Industries 1/29/2025 Earnings Report

3Dx Industries logo
$0.01 0.00 (0.00%)
As of 07/18/2025 03:51 PM Eastern

3Dx Industries EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

3Dx Industries Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

3Dx Industries Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

3Dx Industries Earnings Headlines

Head to Head Comparison: 3Dx Industries (DDDX) and Its Rivals
Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
3DX Industries Provides Update on Latest Developments
See More 3Dx Industries Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 3Dx Industries? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 3Dx Industries and other key companies, straight to your email.

About 3Dx Industries

3Dx Industries (OTCMKTS:DDDX), Inc. (OTCMKTS:DDDX) is a medical technology company focused on the development and commercialization of non-respiratory wearable diagnostic solutions for early disease detection. Its core mission is to deliver point-of-care tests that utilize oral fluid biomarkers, offering a non-invasive alternative to blood draws and other traditional diagnostic methods. By integrating microfluidic and sensor technologies into a compact format, the company aims to bring rapid, accurate testing capabilities to clinical settings, community health centers, and home environments.

The flagship product, OraBD™ (Oral BioDiagnostic) system, is designed to analyze saliva samples for biomarkers linked to autoimmune disorders, infectious diseases, and metabolic conditions. This platform provides results in minutes, enabling healthcare practitioners and patients to make informed decisions without delays associated with laboratory processing. In addition to its lead assay, 3Dx Industries is advancing a pipeline of diagnostic tests targeting neurological and hormonal biomarkers, positioning the company to address a wide spectrum of health conditions with a single point-of-care device.

Originally founded in 2008 under the name InTav Technologies, the company rebranded to 3Dx Industries in 2012 and has since established strategic partnerships with universities, research institutes, and clinical laboratories across the United States. Headquartered in Durham, North Carolina, its R&D and manufacturing operations support both product development and clinical validation efforts. The executive team is led by Chairman and Chief Executive Officer Gilbert O. Nichols, whose background in biomedical innovation has guided the company’s growth. Chief Operating Officer Dr. Christopher Masback oversees technical and operational functions, while Chief Financial Officer Glenn Shook manages finance and investor relations. Under this leadership, 3Dx Industries continues to seek regulatory clearances and collaborative agreements to expand its presence in international markets.

View 3Dx Industries Profile

More Earnings Resources from MarketBeat